Coloplast Vaginal Mesh Postmarket Data Shows Similar Safety To Native Tissue Repair

The company’s review of patient safety data found similar adverse event rates between patients treated with transvaginal mesh and those treated surgically. However, the FDA still says the benefits of the treatment do not outweigh its risks

3D illustration of the number 522 against a maroon background.
• Source: Shutterstock

More from Regulation

More from Policy & Regulation